Bosutinib, an Abl/Src kinase inhibitor currently used to treat patients with chronic myeloid leukemia, inhibits neutrophil FcγR2A-induced ROS production, recruitment to glomerular capillaries and kidney injury in an immune complex-driven model of kidney disease (85) suggesting this may be a promising therapy to target neutrophilic damage in lupus nephritis. The gene discussed is FCGR2A; the disease is lupus nephritis.